Annual EBITDA
-$90.34 M
+$37.66 M+29.42%
31 December 2023
Summary:
Protagonist Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$90.34 million, with the most recent change of +$37.66 million (+29.42%) on 31 December 2023. During the last 3 years, it has fallen by -$28.82 million (-46.84%). PTGX annual EBITDA is now -897.02% below its all-time high of -$9.06 million, reached on 31 December 2014.PTGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$40.81 M
-$2.90 M-7.66%
30 September 2024
Summary:
Protagonist Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$40.81 million, with the most recent change of -$2.90 million (-7.66%) on 30 September 2024. Over the past year, it has dropped by -$3.31 million (-8.82%). PTGX quarterly EBITDA is now -119.70% below its all-time high of $207.13 million, reached on 31 March 2024.PTGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$152.30 M
-$3.31 M-2.13%
30 September 2024
Summary:
Protagonist Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently $152.30 million, with the most recent change of -$3.31 million (-2.13%) on 30 September 2024. Over the past year, it has increased by +$302.20 million (+201.61%). PTGX TTM EBITDA is now -2.13% below its all-time high of $155.61 million, reached on 30 June 2024.PTGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTGX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.4% | -8.8% | +201.6% |
| 3 y3 years | -46.8% | -22.8% | +245.3% |
| 5 y5 years | -130.5% | -157.1% | +311.2% |
PTGX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -46.8% | +29.4% | -119.7% | +1.8% | -2.1% | +201.6% |
| 5 y | 5 years | -130.5% | +29.4% | -119.7% | +1.8% | -2.1% | +201.6% |
| alltime | all time | -897.0% | +29.4% | -119.7% | +1.8% | -2.1% | +201.6% |
Protagonist Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$40.81 M(+7.7%) | $152.30 M(-2.1%) |
| June 2024 | - | -$37.90 M(-118.3%) | $155.61 M(+2.4%) |
| Mar 2024 | - | $207.13 M(+767.3%) | $151.98 M(-268.2%) |
| Dec 2023 | -$90.34 M(-29.4%) | $23.88 M(-163.7%) | -$90.34 M(-39.7%) |
| Sept 2023 | - | -$37.50 M(-9.7%) | -$149.90 M(+4.2%) |
| June 2023 | - | -$41.53 M(+18.0%) | -$143.85 M(+0.7%) |
| Mar 2023 | - | -$35.19 M(-1.4%) | -$142.91 M(+11.6%) |
| Dec 2022 | -$128.00 M(+4.0%) | -$35.68 M(+13.4%) | -$128.00 M(-0.4%) |
| Sept 2022 | - | -$31.45 M(-22.5%) | -$128.53 M(-1.4%) |
| June 2022 | - | -$40.60 M(+100.2%) | -$130.30 M(+8.6%) |
| Mar 2022 | - | -$20.28 M(-44.0%) | -$119.95 M(-2.5%) |
| Dec 2021 | -$123.07 M(+100.0%) | -$36.20 M(+9.0%) | -$123.07 M(+17.4%) |
| Sept 2021 | - | -$33.22 M(+9.8%) | -$104.84 M(+33.2%) |
| June 2021 | - | -$30.25 M(+29.3%) | -$78.74 M(+19.4%) |
| Mar 2021 | - | -$23.40 M(+30.2%) | -$65.92 M(+7.1%) |
| Dec 2020 | -$61.52 M(-18.2%) | -$17.97 M(+152.4%) | -$61.52 M(+3.7%) |
| Sept 2020 | - | -$7.12 M(-59.2%) | -$59.36 M(-12.9%) |
| June 2020 | - | -$17.44 M(-8.2%) | -$68.11 M(-15.8%) |
| Mar 2020 | - | -$19.00 M(+20.3%) | -$80.86 M(+7.5%) |
| Dec 2019 | -$75.19 M | -$15.80 M(-0.5%) | -$75.19 M(+4.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | -$15.87 M(-47.4%) | -$72.12 M(+10.1%) |
| June 2019 | - | -$30.18 M(+126.4%) | -$65.49 M(+47.6%) |
| Mar 2019 | - | -$13.33 M(+4.7%) | -$44.38 M(+13.2%) |
| Dec 2018 | -$39.20 M(+7.2%) | -$12.74 M(+37.9%) | -$39.20 M(+35.6%) |
| Sept 2018 | - | -$9.24 M(+1.9%) | -$28.91 M(+17.8%) |
| June 2018 | - | -$9.07 M(+11.3%) | -$24.55 M(-19.6%) |
| Mar 2018 | - | -$8.15 M(+231.9%) | -$30.52 M(-16.5%) |
| Dec 2017 | -$36.55 M(+13.0%) | -$2.46 M(-49.6%) | -$36.55 M(-19.5%) |
| Sept 2017 | - | -$4.87 M(-67.6%) | -$45.42 M(-4.6%) |
| June 2017 | - | -$15.04 M(+6.0%) | -$47.60 M(+20.3%) |
| Mar 2017 | - | -$14.19 M(+25.3%) | -$39.57 M(+22.3%) |
| Dec 2016 | -$32.35 M(+122.4%) | -$11.32 M(+60.5%) | -$32.35 M(+24.7%) |
| Sept 2016 | - | -$7.05 M(+0.7%) | -$25.94 M(+13.5%) |
| June 2016 | - | -$7.00 M(+0.5%) | -$22.86 M(+21.1%) |
| Mar 2016 | - | -$6.97 M(+41.8%) | -$18.88 M(+29.8%) |
| Dec 2015 | -$14.55 M(+60.5%) | -$4.91 M(+23.7%) | -$14.55 M(+51.0%) |
| Sept 2015 | - | -$3.97 M(+31.1%) | -$9.63 M(+70.2%) |
| June 2015 | - | -$3.03 M(+15.2%) | -$5.66 M(+115.2%) |
| Mar 2015 | - | -$2.63 M | -$2.63 M |
| Dec 2014 | -$9.06 M | - | - |
FAQ
- What is Protagonist Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics annual EBITDA year-on-year change?
- What is Protagonist Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics quarterly EBITDA year-on-year change?
- What is Protagonist Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Protagonist Therapeutics?
- What is Protagonist Therapeutics TTM EBITDA year-on-year change?
What is Protagonist Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PTGX is -$90.34 M
What is the all time high annual EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.06 M
What is Protagonist Therapeutics annual EBITDA year-on-year change?
Over the past year, PTGX annual earnings before interest, taxes, depreciation & amortization has changed by +$37.66 M (+29.42%)
What is Protagonist Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PTGX is -$40.81 M
What is the all time high quarterly EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $207.13 M
What is Protagonist Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PTGX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$3.31 M (-8.82%)
What is Protagonist Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PTGX is $152.30 M
What is the all time high TTM EBITDA for Protagonist Therapeutics?
Protagonist Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $155.61 M
What is Protagonist Therapeutics TTM EBITDA year-on-year change?
Over the past year, PTGX TTM earnings before interest, taxes, depreciation & amortization has changed by +$302.20 M (+201.61%)